Latest Funding News

Elsight Limited has raised A$60 million through a strongly supported placement, marking a milestone with consecutive record revenues and cash flow breakeven. The company is poised to capitalize on surging defence budgets and expanding drone markets with a robust pipeline of opportunities.

Sarama Resources has completed the acquisition of an 80% stake in the Mt Venn Gold Project, boosting its Laverton landholding to 1,000km² across two major projects. The move positions Sarama to explore promising gold and base metal targets in a prolific Australian gold district.

Austco Healthcare reports robust FY25 growth with revenue climbing over 37% and EBITDA soaring by more than 54%, fueled by strong organic performance and key acquisitions.

AdAlta Limited has prioritized two promising CAR-T cellular immunotherapy products for licensing agreements and successfully raised $1.3 million to support its strategic expansion. The company’s focused capital management and pipeline refinement signal a pivotal phase in its ‘East to West’ strategy.

Tetratherix Limited has marked a pivotal quarter with a $25 million ASX listing, an exclusive licensing agreement with Bio Optix for ophthalmic devices, and progress on FDA regulatory submissions for its prostate spacer product.

Argenica Therapeutics has dosed the final patient in its Phase 2 trial for ARG-007 in acute ischaemic stroke, with topline results expected in Q3 2025. Meanwhile, the FDA has placed a clinical hold on its US trial application, introducing uncertainty for US development.

Paladin Energy reported a $18.4 million operating cash outflow in Q2 2025 but maintains a strong liquidity position with $89 million in cash and $139 million in total available funding.

QPM Energy has successfully raised $7 million through an oversubscribed Share Purchase Plan, significantly exceeding its initial $2 million target to accelerate key gas power projects in Queensland.

Astron Corporation has released updated economics for its Donald Rare Earth and Mineral Sands Project, showcasing robust financial metrics and targeting a Final Investment Decision by late 2025 with production slated for 2027.

Nyrada Inc. is set to launch a Phase IIa clinical trial of Xolatryp™, aiming to reduce heart muscle damage in acute myocardial infarction patients undergoing PCI. The trial, planned for early 2026, follows promising Phase I safety results and strong preclinical cardioprotection data.

Race Oncology has safely treated the first patient with its RC220 drug alone and in combination with doxorubicin in a Phase 1 trial, while bolstering its clinical leadership and maintaining a strong cash position to fund operations through 2026.

Plenti Group has reported a third consecutive record quarter with $437 million in loan originations, driven by strong automotive and NAB partnership growth. The fintech lender also secured a key government contract and continues to deliver low credit losses.